Merck & Company, Inc. vs Orthofix Medical Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
6.3
Neutral
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
OFIX
Clean balance sheet with low leverage (0.5× debt-to-equity).
⚠ currently unprofitable (-11% margin).
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $17.25 (+44.8%)
4 analysts
Fundamentals
MRK
OFIX
31.5×
Trailing P/E
—
11.5×
Forward P/E
13.9×
13.6%
Profit Margin
-11.2%
76.6%
Gross Margin
68.8%
—
ROE
-19.3%
4.9%
Revenue Growth
2.0%
—
Earnings Growth
—
0.28
Beta
0.82
—
Price / Book
—
$277.0B
Market Cap
$481M
$73 – $125
52-Week Range
$10 – $17
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →